Can the instruction be e-signed?

Yes. Electronic signatures are generally enforceable under the ESIGN Act (15 U.S.C. ch. 96) and state UETA laws when intent, consent, attribution, and retention are documented. Exceptions exist for a few categories such as wills or certain court filings; confirm with your IRB and legal counsel.

What makes an e-signature valid?

Valid e-signatures require demonstrated signer intent, consent to transact electronically, clear attribution to the signer, and reliable record retention and reproduction. For consumer-facing healthcare records, follow ESIGN consumer-disclosure requirements when applicable.

How do we meet HIPAA requirements?

Use a HIPAA-capable platform and execute a Business Associate Agreement (BAA) with the vendor. Ensure PHI access is role-limited, audit logs are enabled, and encryption and session controls are in place.

Who is authorized to sign?

Signatories should be identified in the protocol or sponsor agreement; participants must sign consent before procedures, and authorized site staff sign operational confirmations. Confirm authority in delegation logs and sponsor contracts.

How do we revoke or correct an instruction?

Issue a superseding version with a new effective date and distribute via the same controlled workflow. For signed records, document the reason for revision and maintain both versions with version history for audit.

What common errors cause inspection findings?

Typical issues include missing signatures or dates, unclear version control, insufficient consent language, lack of audit trails, and inadequate authentication. Address these proactively through standardized templates and routine quality checks.

Electronic Signature
Templates
Healthcare
Healthcare Clinical Trial Instruction

Healthcare Clinical Trial Instruction

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

Healthcare Clinical Trial Instruction

Study Identification

Protocol / Study Title:

Sponsor: Study Number:

Study Site: Principal Investigator:

Participant Information

Full legal name Date of birth Gender Address Phone Email

Emergency Contact

Name Relationship Phone

Insurance / Billing

Primary insurance provider Policy number Group number Subscriber name

Medical History (relevant to study)

Current medications (include dose and frequency) Allergies (drug, food, environmental) Prior surgeries / hospitalizations (relevant) Chronic medical conditions

Instruction Summary (Study Procedures & Participant Duties)

The following instructions are provided to ensure safety and data integrity. Participant must follow all directions of the Principal Investigator and study staff. Deviations may require notification and may affect continued participation.

Investigational product administration schedule Clinical visit schedule and required procedures

Missed dose procedure:

Storage and handling of investigational product (including refrigeration or restricted dispensing):

Adverse Events, Safety & Reporting

Participant must report any unexpected or significant symptoms to study staff immediately. Serious adverse events (life-threatening events, hospitalization, persistent disability) must be reported to the study site within 24 hours.

Site contact for adverse events (24/7 if applicable) On-call / emergency contact

Concomitant Medications, Pregnancy & Contraception

Participant must notify study staff prior to initiating any new prescription, over-the-counter medication, herbal supplement, or vaccine. Women of childbearing potential must follow contraception requirements stated in the protocol and notify staff immediately if pregnancy is suspected.

Restrictions or prohibited medications (as provided by investigator)

Confidentiality & Privacy Authorization

Study records, including medical and research data, will be maintained in confidence to the extent required by law. Authorized study personnel and regulatory bodies may review identifiable information for monitoring, safety oversight, or audit purposes. The participant authorizes release of pertinent medical information to the study sponsor and its designees for purposes of study conduct and safety monitoring.

Authorization expiration date:

I authorize the study team to consult my primary care provider or other treating clinicians as necessary to obtain relevant medical records for the safe conduct of this study.

Participant Rights & Withdrawal

Participation is voluntary. The participant has the right to withdraw from the clinical trial at any time without penalty or loss of benefits to which the participant is otherwise entitled. Withdrawal may require follow-up safety assessments as described in the protocol.

If the participant elects to withdraw, they should notify the Principal Investigator or study staff by contacting:

Participant Acknowledgment (Please read and check to confirm)

I have received verbal and written instructions for the above clinical trial procedures and requirements. I understand the dosing schedule, visit schedule, and safety reporting obligations.

I understand that if I experience a severe or unexpected adverse event I must contact study staff immediately and that serious events must be reported within 24 hours.

I have had the opportunity to ask questions about these instructions and received answers. I agree to follow the instructions provided to the best of my ability.

Certification

By signing below I certify that the information provided on this form is true and complete to the best of my knowledge; that I have received and understand the clinical trial instructions; and that I agree to comply with the study procedures and to notify study staff promptly of any adverse events or changes in my medical condition.

Participant Printed Name:

Signature:

Date:

If signed by guardian or legally authorized representative, state relationship:

What the Healthcare Clinical Trial Instruction Is

A Healthcare Clinical Trial Instruction is a formal document that sets out procedures, participant responsibilities, and operational steps for a specific clinical study or task within a study. It clarifies informed consent prerequisites, specimen handling, visit schedules, safety reporting expectations, data collection formats, and roles for site and sponsor staff. The instruction supports regulatory compliance by describing recordkeeping, privacy safeguards for protected health information, and any required authentication or witness steps for signature. Use this document to reduce ambiguity and document consistent execution across sites and participants.

Why a Clear Instruction Matters for Trials

A concise instruction improves protocol adherence, reduces protocol deviations, and documents consent and procedural steps used during a trial. It also helps demonstrate compliance with HIPAA privacy standards and applicable FDA or institutional requirements.

Who Prepares and Who Receives These Instructions

Typical preparers and recipients include clinical operations, principal investigators, study coordinators, and sponsor monitors.

Study Sponsor teams and clinical operations who set protocol-level instructions for multiple sites.
Site investigators and coordinators who implement procedures and collect consent and data at the point of care.
Institutional Review Boards (IRBs) or ethical committees that review instruction clarity and participant protections.

Use clear authoring and version control so each recipient uses the correct, approved instruction set.

Step-by-step: Completing a Clinical Trial Instruction

Follow these core steps to create, approve, distribute, and archive an instruction reliably across sites.

01

Draft: Author the instruction aligned to protocol and consent language.
02

Review: Obtain clinical, regulatory, and legal review before approval.
03

Approve: Record IRB or sponsor approvals and version metadata.
04

Distribute: Deliver the approved file to sites with tracking and receipt confirmation.

How to set up the instruction as an online workflow

Configure fields, routing, and authentication to match site processes and compliance needs.

Field	Configuration
Signature Field	Required; capture date and IP address
Conditional Steps	Show extra fields when adverse events are reported
Authentication	Email + SMS OTP or KBA for higher assurance
Audit Trail	Enable full action logging and export

Where the instruction goes and how it’s routed

Typical routing follows a defined approval and distribution chain to ensure each stakeholder receives the correct version.

Site Upload: Coordinator stores the approved instruction in the site trial folder.
Sponsor Archive: Sponsor retains a master, versioned copy for inspection.
IRB Submission: Attach instruction to IRB amendments when procedures change.
Participant Copy: Provide participant-facing instructions when applicable.

Digital signing and platform requirements

Select a platform that supports audit trails, secure storage, and required authentication for healthcare data.

Security: TLS in transit; AES-256 at rest
Compliance: HIPAA-ready with a BAA
Integrations: Supports EHR and document management

Ensure the chosen system can export certified audit logs, preserve tamper-evidence, and meet any sponsor or regulator-specific authentication requirements.

Key timing considerations for instructions

Be aware of timing expectations tied to consent, reporting, and filing so the instruction does not create compliance gaps.

Consent Before Procedures:

Obtain and record consent prior to any study-specific intervention or data collection.

IRB Reporting Windows:

Report serious adverse events per IRB and sponsor timelines; follow local reporting policies.

Version Effective Date:

State the effective date clearly so sites use the correct version.

Record Availability:

Ensure records are accessible for monitoring and inspection on request.

Sponsor Notification:

Notify sponsor of protocol deviations promptly per contract terms.

Milestones from drafting to archive

A typical milestone sequence tracks authoring, approvals, distribution, monitoring, and archival for audit readiness.

01

Draft Completion

Author completes initial instruction and documents rationale.

02

Regulatory Review

IRB and regulatory teams review for human subject protections.

03

Site Distribution

Approved version distributed to active sites with receipt confirmation.

04

Archival

Retain master and site copies per retention policy.

Common preparation errors to avoid

Using ambiguous procedural language that leads to inconsistent execution across sites and protocol deviations.
Failing to version-control the instruction, causing sites to use superseded or unapproved procedures.
Neglecting required consent language or privacy disclosures required under HIPAA that affect participant rights.
Omitting audit trail settings or weak signer authentication that undermines evidence of intent and attribution.

Risks and regulatory consequences of incorrect instructions

HIPAA Violation: Potential civil penalties and corrective action

Protocol Deviation: May jeopardize trial integrity and data

Invalid Consent: Could render participant data unusable

Inspection Findings: Favorable audit outcomes may be compromised

Legal Liability: Increased sponsor or site exposure

Study Delays: Regulatory holds or slowed enrollment

Security and compliance checklist

Encryption: AES-256 at rest

Transport Security: TLS 1.2/1.3 in transit

Audit Trails: Timestamped action logs retained

HIPAA BAA: BAA required for PHI handling

21 CFR Part 11: Controls for FDA-regulated records

Access Controls: Role-based permissions enforced

eSignature vendor comparison for healthcare trial documents

Compare core pricing and compliance features when selecting an eSignature provider for clinical trial instructions; ensure HIPAA support and audit capability.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	Varies by plan	Varies by plan	Varies by plan	Varies by plan
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No
Envelope Cap	No envelope cap	100 envelopes/user/year	Varies by plan	Varies by plan	Varies by plan

Real-world examples and vendor customer context

Two representative customer stories show how electronic execution supported compliance and operations.

Fertility Centers Example

John Butler, Founder

The team improved signature turnaround on patient forms
The organization cited faster execution, reliable audit trails, and strong API support for integration with clinical systems, which simplified retrieval during audits and monitoring visits.

Optica Ventures Example

Brian Fitzgibbons, COO

Internal and external users found the interface straightforward
The result was more consistent document returns across stakeholders and reduced follow-up time for missing signatures, improving study administrative throughput.

Frequently asked questions about Clinical Trial Instructions

Answers cover legality, signatures, privacy, and common operational issues when implementing instructions across study sites.

Need help? Contact support

Can the instruction be e-signed?
Yes. Electronic signatures are generally enforceable under the ESIGN Act (15 U.S.C. ch. 96) and state UETA laws when intent, consent, attribution, and retention are documented. Exceptions exist for a few categories such as wills or certain court filings; confirm with your IRB and legal counsel.
What makes an e-signature valid?
Valid e-signatures require demonstrated signer intent, consent to transact electronically, clear attribution to the signer, and reliable record retention and reproduction. For consumer-facing healthcare records, follow ESIGN consumer-disclosure requirements when applicable.
How do we meet HIPAA requirements?
Use a HIPAA-capable platform and execute a Business Associate Agreement (BAA) with the vendor. Ensure PHI access is role-limited, audit logs are enabled, and encryption and session controls are in place.
Who is authorized to sign?
Signatories should be identified in the protocol or sponsor agreement; participants must sign consent before procedures, and authorized site staff sign operational confirmations. Confirm authority in delegation logs and sponsor contracts.
How do we revoke or correct an instruction?
Issue a superseding version with a new effective date and distribute via the same controlled workflow. For signed records, document the reason for revision and maintain both versions with version history for audit.
What common errors cause inspection findings?
Typical issues include missing signatures or dates, unclear version control, insufficient consent language, lack of audit trails, and inadequate authentication. Address these proactively through standardized templates and routine quality checks.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now